Diplomat to Dispense DUPIXENT® to Treat Atopic Dermatitis

FLINT, Mich., March 28, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) will have access to dispense DUPIXENT^® (dupilumab), recently approved by the Food and Drug Administration to treat adult patients who have inadequately controlled moderate-to-severe atopic dermatitis.

To learn more about Diplomat's dermatology program, visit diplomat.is/areas-of-excellence/dermatology.

Atopic dermatitis (AD), the most common form of eczema, is an inflammatory disease characterized by itchy, inflamed skin. According to the National Institutes of Health, it affects approximately 30 percent of people in the United States. DUPIXENT^® is a monoclonal antibody that works with the immune system and has demonstrated improved signs and symptoms in adult patients with inadequately controlled moderate-to-severe AD.

"Moderate-to-severe atopic dermatitis is a debilitating, life-altering disease with very limited treatment options," said Paul Urick, Diplomat's president. "We are thrilled to offer this new option for patients with unmet needs."

DUPIXENT^® is administered through subcutaneous injection. 

DUPIXENT^® is co-developed by Sanofi and Regeneron Pharmaceuticals, Inc. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-dupixent-to-treat-atopic-dermatitis-300430710.html

SOURCE Diplomat Pharmacy, Inc.